Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in addiction treatment with a current market capitalization of $5 million, has been granted a new ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

ENCINITAS, CA - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a small-cap biotech firm with a market capitalization of $10.47 million and strong financial health according to InvestingPro analysis, has ...

The breakthrough in drug delivery hinges on the development of nanoarchaeosomes, which are nanoparticles loaded with ...

Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...

With the recent convocation of the 119th Congress, a change in administration, and resignation of USPTO Director Vidal, pharmaceutical patent ...

Drug patents are used, and sometimes abused, as a way to protect pharma profits by limiting competition. From gamesmanship with patent thickets to questionable practices with the FDA Orange Book ...